Jefferies Upgrades Scotts Miracle-Gro on Cannabis Recovery Thesis

Jefferies analysts have upgraded The Scotts Miracle-Gro Company (SMG) to a buy rating, betting on a recovery in the company's cannabis cultivation business after two years of steep declines. The investment bank's bullish stance reflects growing confidence that the worst of the downturn in SMG's Hawthorne Gardening subsidiary has passed, with stabilizing demand for hydroponic equipment and nutrients signaling potential earnings recovery ahead.

Cannabis Unit Shows Signs of Bottoming

Scotts Miracle-Gro's Hawthorne division, which supplies equipment and nutrients to cannabis growers, has been a major drag on the company's financial performance since 2022. The unit's revenue collapsed from a peak of over $1 billion in 2021 to approximately $400 million in 2023, as oversupply in legal cannabis markets reduced grower demand for cultivation inputs. However, recent quarterly results suggest the decline may be moderating, with Hawthorne posting smaller year-over-year decreases in recent quarters compared to the dramatic drops seen throughout 2022 and early 2023.

The upgrade comes as cannabis cultivation markets show early signs of rationalization. State-level data indicates that flower prices have begun stabilizing in key markets like California and Colorado after falling precipitously for two years. This price stabilization typically precedes renewed investment in cultivation infrastructure, which would directly benefit Hawthorne's equipment and nutrient sales.

Valuation Reflects Pessimistic Outlook

SMG shares have underperformed the broader market significantly, trading at levels that appear to price in permanent impairment of the Hawthorne business. The stock trades at approximately 12 times forward earnings, well below its historical average of 18-20 times, despite the company's dominant consumer lawn care franchise remaining intact. Jefferies analysts argue this valuation disconnect creates an asymmetric risk-reward profile, where even modest recovery in cannabis cultivation demand could drive substantial share price appreciation.

The company's balance sheet remains solid despite Hawthorne's struggles, with management maintaining its dividend and avoiding significant debt accumulation during the downturn. This financial stability provides a cushion while the cannabis cultivation market works through its oversupply issues.

Regulatory Tailwinds Building

Broader regulatory developments in cannabis also support the recovery thesis. The Drug Enforcement Administration's ongoing review of cannabis scheduling could accelerate market normalization by reducing regulatory uncertainty that has constrained business investment. Additionally, new state markets continue coming online, with recent launches in New York and New Jersey adding cultivation capacity that requires Hawthorne's products.

The cannabis cultivation market appears to be transitioning from a period of destructive oversupply to more rational capacity planning, which should benefit equipment suppliers like Hawthorne.

Federal banking reforms, while still pending, could also unlock additional capital for cannabis operators to invest in facility upgrades and expansion, directly benefiting cultivation equipment suppliers.

Consumer Business Provides Stability

While cannabis recovery drives the upgrade thesis, Scotts Miracle-Gro's core consumer lawn and garden business continues generating steady cash flows. This division, which includes iconic brands like Miracle-Gro fertilizer and Ortho pesticides, benefits from the company's dominant retail relationships and seasonal demand patterns that remain largely recession-resistant.

The consumer segment's stability allows management to maintain dividend payments and invest in operational improvements while waiting for Hawthorne to recover. This dual-business model structure provides downside protection that pure-play cannabis stocks lack.

Risk Factors Remain

Despite the upgrade, significant risks persist around the cannabis recovery timeline. State-level oversupply conditions vary widely, and some markets may require additional quarters of rationalization before grower demand normalizes. Federal rescheduling delays could also extend the period of regulatory uncertainty that constrains business investment in cannabis cultivation.

Additionally, changing cultivation practices toward more efficient growing methods could permanently reduce demand for certain Hawthorne products, limiting the unit's revenue recovery potential even as market conditions improve.

The Jefferies upgrade represents a contrarian bet that cannabis cultivation markets have reached an inflection point after an extended downturn. For SMG shareholders, the thesis offers hope that the company's patient approach through the cannabis winter will eventually pay dividends as market conditions normalize and grower demand recovers.